Sinew Pharma Inc. (TPEX:6634)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
38.15
+0.75 (2.01%)
Apr 20, 2026, 1:03 PM CST
Market Cap2.67B -24.2%
Revenue (ttm)47.00K
Net Income-123.75M
EPS-1.74
Shares Out71.29M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,000
Average Volume67,575
Open35.70
Previous Close37.40
Day's Range35.70 - 39.40
52-Week Range29.05 - 56.50
Beta-0.04
RSI66.57
Earnings DateAug 13, 2026

About Sinew Pharma

Sinew Pharma Inc., a biopharmaceutical company, focuses on the research, development, and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases. The company’s products include SNP-610 drug, which is in Phase IIa clinical trial and SNP-630 drug, which is in Phase II clinical trial for treating patients with non-alcoholic steatohepatitis in Taiwan. It is also developing SNP-810 is in phase II clinical trial for use in pain relief and fever reduction; SNP-820 is in Phase II clinical trial for antidote for ac... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 48
Stock Exchange Taipei Exchange
Ticker Symbol 6634
Full Company Profile

Financial Performance

Financial Statements